Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update


ZUG, Switzerland, April 10, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update.

Go here to see the original:
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Related Posts